Brief: Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301

Cingulate

04/03/2025 14:05

March 4 (Reuters) - Cingulate Inc CING.O:

CINGULATE REPORTS SAFETY RESULTS FROM FINAL PHASE 3 TRIALS FOR LEAD ADHD ASSET CTX-1301: ON TRACK TO FILE FOR FDA APPROVAL MID-2025

CINGULATE INC - NO SERIOUS ADVERSE EVENTS REPORTED IN CTX-1301 STUDIES

Source text: ID:nGNX6DHw88

Further company coverage: CING.O

 (Reuters.Briefs@thomsonreuters.com)